IPO

Anthem Biosciences Limited IPO

Mainboard Pre-Apply

Offer Date: Jul 14, 2025 - Jul 16, 2025

Exp. Premium: 98-100 (17.19%)

₹ 14820 /26 Shares

Pre-Apply

*Expected Premium provided in this app is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.

Anthem Biosciences IPO Details

14 Jul, 2025

Open Date

16 Jul, 2025

Close Date

17 Jul, 2025

Allotment Date

21 Jul, 2025

Listing Date

Issue Price

₹540-570 per equity share

Face Value

₹2 Per Equity Share

Listing at Group

BSE, NSE

Registrar

Kfin Technologies Limited

Market Lot

Retail : 26 Shares (₹14,820/-)
S-HNI : 364 Shares (₹2,07,480/-)
B-HNI : 1,768 Shares (₹10,07,760/-)

Lead Manager

Jm Financial Limited
Citigroup Global Markets India Private Limited
J.P. Morgan India Private Limited
Nomura Financial Advisory And Securities (India) Pvt Ltd

Issue Size

OFS : 5,95,61,404 shares(aggregating up to ₹3395.00 Cr)

Retail Portion

35% (Number of Retail Applications: 7,99,840 Approx),
(Number of S-HNI Applications : 8,162 Approx),
(Number of B-HNI Applications : 16,323 Approx)

Subscription

N/A times

Anthem Biosciences IPO Details


Anthem Biosciences IPO is a book-built issue of ₹3395 crores, The total issue size is ₹3395 crores. The IPO of Anthem Biosciences is priced at ₹540-570 per equity share, which has a face value of ₹2 Per Equity Share each, IPO bidding starts from Jul 14, 2025 and ends on Jul 16, 2025. The allotment for Anthem Biosciences IPO will be finalized on Jul 17, 2025. Anthem Biosciences IPO will be listed on BSE, NSE, with a tentative listing date fixed as Jul 21, 2025. The company shall list its equity shares on the BSE, NSE. Kfin Technologies Limited is the registrar of the issue.

Retail investors can bid for a minimum of 26 shares, extendable to 14,820. S-HNIs will be able to bid for 364 shares at ₹2,07,480, while B-HNIs can also apply for a bid of 1,768 shares at ₹10,07,760. The book-running lead manager for the IPO is/are Jm Financial Limited , Citigroup Global Markets India Private Limited , J.P. Morgan India Private Limited , Nomura Financial Advisory And Securities (India) Pvt Ltd .

an Offer for Sale (OFS) of 5,95,61,404 shares to mop up ₹3395 crore.

The Anthem Biosciences IPO sets its price band at 540-570 for each share. A single application for Anthem Biosciences Limited IPO must contain at least 26 shares. Sentiment investors need to invest a minimum of 26 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,820 In order to participate in the sNII, investors must purchase at least 14 lots of 364 shares for ₹2,07,480, while the bNII requires 68 lots of 1,768 shares for an investment of ₹10,07,760.

Read More

Anthem Biosciences Valuations

EPS Pre IPO

₹8.07/-

EPS Post IPO

₹8.07/-

P/E Pre IPO

70.62

P/E Post IPO

70.62

ROE

20.82%

ROCE

26.88%

Debt/Equity

0.05

RoNW

20.82%

PAT Margin

23.38%

Price to Book Value

13.23

Anthem Biosciences Company Financials All values are in ₹ Cr.

31-Mar-2531-Mar-2431-Mar-23
Assets2,807.582,398.112,014.46
Revenue1,930.291,483.071,133.99
Profit After Tax451.26367.31385.19
Net Worth2,409.861,924.661,740.67
Reserves & Surplus2,298.051,815.391,628.88
Total Borrowing108.95232.53125.06

About The Company

Founded in 2006, Anthem Biosciences Limited is a technology and innovation-led Contract Research, Development, and Manufacturing Organization (CRDMO) with vertically integrated operations covering drug discovery, development, and manufacturing activities.

The company caters to varied customers such as innovative, early-stage biotech companies and big pharma companies globally.The company produces niche fermentation-based APIs, such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.For the half-year ended September 30, 2024, the company was involved in the production of active pharmaceutical ingredients (API) and intermediates for ten commercial molecules, all of which have been funded since discovery.

The company had 196 projects as of September 30 2024: 170 discovery projects (284 synthesized molecules), 132 early phase projects, 16 late phase projects (10 late phase molecules), and 13 commercial manufacturing projects (API and intermediates for 10 commercialized molecules).

As of March 31, 2024, and September 30, 2024, the company had more than 425 and 550 customers for our CRDMO and specialty ingredients business, distributed across more than 44 countries, including Europe, Japan, and the U.S.As of March 31, 2024, the company had more than 150 customers, ranging from small biotech to big pharma.As of 30 September 2024, the company has one patent in India, seven foreign, and 24 pending foreign patent applications, including process patents for glycolipid synthesis and GLP-1 analogues.

As of 30 September 2024, the company has 600 employees, including medicinal chemists, microbiologists, molecular biologists, biochemists, specialists in different in-vivo non-clinical research and chemical engineers.

Read More

Anthem Biosciences - Strength and Weakness

Strength

Fastest Indian CRDMO to cross ₹10,000 million revenue in 14 years.

Offers integrated CRDMO services across both small molecules and biologics.

Serves diverse global clients including Bayer AG and emerging biotech.

Operating India’s largest fermentation capacity of 142 kL as of Sep 2024

Weakness

CRDMO services contributed 81.13% revenue; demand decline may hurt.

Top 10 customers contributed 76.75% revenue; loss impacts business.

Regulatory non-compliance may disrupt exports, approvals, and customer confidence.

Underused capacity and poor forecasts could hurt future performance.

Anthem Biosciences - Peers Comparison

P/B RatioP/E RatioRoNWNet Worth
Anthem BiosciencesN/AN/A20.8%1844
Syngene International6.2151.5411.05%4642
Sai Life Sciences7.4592.1810.96%1694
Cohan Lifesciences14.1197.2913.61%1197
Divi's Lab10.2483.2215.35%9360

Anthem Biosciences - Promoter(s)

Pre Issue Share Holding: 77.23%

Post Issue Share Holding: 74.68%


Company Promoter(s)
  1. Ajay Bhardwaj
  2. Ganesh Sambasivam
  3. K Ravindra Chandrappa
  4. Ishaan Bhardwaj

Anthem Biosciences IPO - Issue Objectives

  1. The Company will not receive any proceeds from the Offer (the “Offer Proceeds”) and all the Offer Proceeds will be received by the Selling Shareholders after deduction of Offer related expenses and relevant taxes thereon, to be borne by the respective Selling Shareholders.

Anthem Biosciences IPO - Anchor Investors

Anthem Biosciences IPO: Institutional buyers select Rs 1,016 crore worth of shares through anchor book.

World marquee investors such as Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, Optimix Wholesale Global Emerging Markets Share Trust, PineBridge Global Funds, and Societe Generale acquired the pharma firm's shares through anchor book.

Most asset management firms such as HDFC Mutual Fund, ICICI Prudential AMC, Kotak Mahindra Trustee, Nippon Life India Trustee, Aditya Birla Sun Life AMC, Axis Mutual Fund, Whiteoak Capital Mutual Fund, Franklin, Mirae Asset, UTI MF, Motilal Oswal MF, Quant Mutual Fund, Edelweiss Trusteeship, and Bandhan Mutual Fund also invested the lion's share of money (approximately Rs 604.4 crore) in to Anthem Biosciences through anchor book.

Other Details

Company Contact Details

Anthem Biosciences

No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099

Phone: +91 080 6672 400

Email: investors.abl@anthembio.com

Website: https://www.anthembio.com/

Registrar Contact Details

Kfin Technologies Limited

Phone: 04067162222, 04079611000

Email: anthem.ipo@kfintech.com

Website: https://kosmic.kfintech.com/ipostatus/

Anthem Biosciences IPO - FAQs

Ans. Anthem Biosciences Limited IPO is a Mainboard IPO. The issue is priced at ₹540-570 per equity share. The minimum order quantity is 26 Shares. The IPO opens on Jul 14, 2025, and closes on Jul 16, 2025. Kfin Technologies Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Anthem Biosciences Limited IPO opens on Jul 14, 2025 and closes on Jul 16, 2025.

Ans. The size of Anthem Biosciences Limited IPO is OFS : 5,95,61,404 shares(aggregating up to ₹3395.00 Cr).

Ans. The IPO price band is set between ₹540-570 per equity share.

Ans. To apply for Anthem Biosciences Limited IPO IPO, follow the steps given below:

  • - Open the IPO Ji App or Website
  • - Find Anthem Biosciences Limited IPO in the List of IPOs
  • - Press "Apply" Button
  • - Select Your Demat Account
  • - Select Your Shares Quantity and Submit
  • - Track Your IPO Status

Ans. The share allotment date of Anthem Biosciences Limited IPO is Jul 17, 2025.

Ans. The Anthem Biosciences Limited IPO will be listed on Jul 21, 2025.

Ans. Follow the steps to check the allotment status for Anthem Biosciences Limited IPO here.

Anthem Biosciences Limited IPO
Anthem Biosciences Limited IPO

Offer Date

Jul 14 - Jul 16, 2025

Offer Price

₹ 540-570

Lot Size

26


Login - IPO JI

Please login to Apply IPO